Plain-English translation of NCT07309185 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining three medications—, Famitinib, and —works better than taking alone for advanced stomach cancer that has stopped responding to first-line treatment. The trial will first carefully watch a small group of patients for 3 months to make sure the three-drug combination is safe. If it is, the study will then enroll 60 more patients and randomly assign them to either receive the new combination or the standard single drug.
Advanced stomach cancer that has stopped responding to initial treatment has very limited options. Researchers believe that combining this medication with two others might help patients live longer or control their cancer better than the current standard approach.
You likely qualify if…
You likely don't qualify if…
First, 6 patients will start the new three-drug combination and be closely monitored for 3 months to check for serious side effects. If the combination appears safe, 60 additional patients will be enrolled and randomly assigned to either receive the three-drug combination or the standard single drug. Participants in the treatment group will receive injections and oral medication on a repeating 3-week schedule, continuing until their cancer worsens, side effects become unbearable, or they have received treatment for at least 2 years. Participants will visit the clinic regularly for blood tests, imaging scans, and doctor check-ins to track how well the treatment is working.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shandong Tumor Hospital
Enrollment target
~66 participants
Started
July 2024
Primary completion
July 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bo Liu, Prof.
Shandong First Medical University Affiliated Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.